Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 9 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results

Data Visualizations

Phase Distribution

8Total
Not Applicable (2)
P 1 (4)
P 2 (2)

Trial Status

Recruiting6
Active Not Recruiting2
Not Yet Recruiting1

Clinical Trials (9)

Showing 9 of 9 trials
NCT04857528Recruiting

Detecting HPV DNA in Anal and Cervical Cancers

NCT05639972Phase 1Recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05686226Phase 2Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

NCT03260023Phase 1Active Not Recruiting

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

NCT06640283Phase 2Recruiting

Dynamic ctDNA Assessment in Cervical and Anal Canal Tumors: Optimizing Follow-up and Clinical Outcomes

NCT05973487Phase 1Active Not Recruiting

A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors

NCT06628570Not ApplicableRecruiting

Screening Strategies Among High-risk Populations for Anal Cancer

NCT03061435Not ApplicableRecruiting

Screening for Anal Cancer in Women With High-grade Vulvar Dysplasia or Vulvar Cancer.

NCT06505551Phase 1Not Yet Recruiting

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Showing all 9 trials

Research Network

Activity Timeline